Illinois Municipal Retirement Fund Raises Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Illinois Municipal Retirement Fund boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.9% in the 4th quarter, Holdings Channel reports. The firm owned 14,146 shares of the company’s stock after acquiring an additional 1,505 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Krystal Biotech were worth $2,216,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Segall Bryant & Hamill LLC lifted its holdings in shares of Krystal Biotech by 352.4% in the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after buying an additional 122,407 shares in the last quarter. State Street Corp increased its holdings in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after acquiring an additional 119,936 shares during the period. Franklin Resources Inc. lifted its stake in Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares in the last quarter. Braidwell LP boosted its holdings in Krystal Biotech by 57.4% in the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after purchasing an additional 61,512 shares during the period. Finally, TimesSquare Capital Management LLC grew its position in shares of Krystal Biotech by 39.1% during the 4th quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock valued at $24,888,000 after purchasing an additional 44,646 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

KRYS has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, February 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Citigroup lifted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Finally, Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $215.83.

Krystal Biotech Price Performance

Shares of KRYS opened at $173.35 on Friday. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The stock has a 50 day simple moving average of $159.13 and a two-hundred day simple moving average of $175.30. The firm has a market cap of $4.99 billion, a P/E ratio of 57.98 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the business posted $0.30 earnings per share. The company’s revenue was up 116.4% on a year-over-year basis. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).